Immunovant Inc Cash Flow-to-Debt Ratio
Immunovant Inc cash flow-to-debt ratio. Immunovant Inc (IMVT) has a Cash Flow-to-Debt Ratio of -1.06x as of June 2026, meaning its operating cash flow of $-124.41 Million could theoretically repay -1% of its total liabilities ($117.10 Million) in one year. Check Immunovant Inc (IMVT) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Immunovant Inc (2018–2026)
Cash flow-to-debt ratio of Immunovant Inc from 2018 to 2026. Historical debt coverage capacity for Immunovant Inc across 9 annual periods. Also explore IMVT shareholders equity momentum to track the company's year-over-year net asset growth rate.
Immunovant Inc Cash Flow-to-Debt Ratio by Year (2018–2026)
Immunovant Inc cash flow-to-debt ratio by year from 2018 to 2026. Year-by-year debt coverage analysis for Immunovant Inc. For the full cash flow conversion analysis, see IMVT cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -3.88x | $-407.31 Million | $104.97 Million | ▲ +29.0% |
| 2025 | -5.47x | $-375.87 Million | $68.78 Million | ▼ -24.9% |
| 2024 | -4.38x | $-214.23 Million | $48.95 Million | ▼ -0.8% |
| 2023 | -4.34x | $-188.19 Million | $43.34 Million | ▼ -87.2% |
| 2022 | -2.32x | $-106.11 Million | $45.74 Million | ▲ +41.5% |
| 2021 | -3.97x | $-83.33 Million | $21.01 Million | ▼ -13.9% |
| 2020 | -3.48x | $-53.36 Million | $15.32 Million | ▲ +95.4% |
| 2019 | -75.04x | $-28.55 Million | $380.45K | ▲ +5.8% |
| 2018 | -79.69x | $-128.30 Million | $1.61 Million | — |